GSK GSK plc

   By Ian Walker 
 

GSK said Friday that it has now sold 240 million shares in consumer healthcare business Haleon for 335 pence each, raising 804 million pounds ($1.01 billion), as first announced late Thursday.

The pharmaceutical giant said Thursday night that it was selling the shares via an accelerated bookbuild. The sale price is a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday.

Following the sale GSK will continue to hold 955 million Haleon shares, or 10.3% of its issued share capital.

Haleon--which includes well-known brands such as Sensodyne and Voltaren--was formed in July 2019 between GSK and Pfizer via the merger of their consumer healthcare businesses into a new joint-venture company.

It was spun out and listed on the London Stock Exchange last July. Pfizer has a 32% shareholding in Haleon.

GSK and Pfizer have agreed not to sell any further Haleon shares for 60 days.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

May 12, 2023 02:32 ET (06:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.